



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 5102

<b>SERIAL NUMBER</b> 10/509,417	<b>FILING OR 371(c) DATE</b> 05/12/2005 <b>RULE</b>	<b>CLASS</b> 514	<b>GROUP ART UNIT</b> 1615	<b>ATTORNEY DOCKET NO.</b> PG4791USw
------------------------------------	---	---------------------	-------------------------------	---

**APPLICANTS**

Rachael Ann Ancliff, Hertfordshire, UNITED KINGDOM;  
 Caroline Mary Cook, Hertfordshire, UNITED KINGDOM;  
 Colin David Eldred, Hertfordshire, UNITED KINGDOM;  
 Paul Martin Gore, Hertfordshire, UNITED KINGDOM;  
 Lee Andrew Harrison, Hertfordshire, UNITED KINGDOM;  
 Martin Alistair Hayes, Hertfordshire, UNITED KINGDOM;  
 Simon Teanby Hodgson, Hertfordshire, UNITED KINGDOM;  
 Duncan Bruce Judd, Hertfordshire, UNITED KINGDOM;  
 Suzanne Elaine Keeling, Hertfordshire, UNITED KINGDOM;  
 Xiao Qing Lewell, Hertfordshire, UNITED KINGDOM;  
 Gail Mills, Hertfordshire, UNITED KINGDOM;  
 Graeme Michael Robertson, Hertfordshire, UNITED KINGDOM;  
 Stephen Swanson, Hertfordshire, UNITED KINGDOM;  
 Andrew John Walker, Hertfordshire, UNITED KINGDOM;  
 Mark Wilkinson, Hertfordshire, UNITED KINGDOM;

**\*\* CONTINUING DATA \*\*\*\*\***

This application is a 371 of PCT/EP03/03339 03/27/2003

**\*\* FOREIGN APPLICATIONS \*\*\*\*\***

UNITED KINGDOM 0207449.0 03/28/2002

Foreign Priority claimed 35 USC 119 (a-d) conditions met	<input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance	<b>STATE OR COUNTRY</b> UNITED KINGDOM	<b>SHEETS DRAWING</b>	<b>TOTAL CLAIMS</b> 8	<b>INDEPENDENT CLAIMS</b> 6
Verified and Acknowledged	Examiner's Signature _____ Initials _____				

**ADDRESS**

23347

**TITLE**

N-2s-4-3,4-difluorobenzyl morpholin-2yl methyl -2-(3-methylsulphonyl amino)phenyl acetamide as ccr3 antagonist for the treatment of inflammatory conditions

**FILING FEE RECEIVED**  
1308

FEES: Authority has been given in Paper  
 No. \_\_\_\_\_ to charge/credit DEPOSIT ACCOUNT  
 No. \_\_\_\_\_ for following:

☐ All Fees

☐ 1.16 Fees ( Filing )

☐ 1.17 Fees ( Processing Ext. of time )

☐ 1.18 Fees ( Issue )

		<input type="checkbox"/> Other _____ <input type="checkbox"/> Credit _____
--	--	---